Company Filing History:
1 out of 2 
1 out of 205 
1 out of 38 Years Active: 2025
Title: Sandy Fabre: Innovator in Cannabinoids-Related Disorders
Introduction
Sandy Fabre is a notable inventor based in Bordeaux, France. He has made significant contributions to the field of cannabinoid research, particularly through his innovative patent related to the treatment of cannabinoids-related disorders. His work has the potential to impact the medical community and improve treatment options for patients.
Latest Patents
Sandy Fabre holds a patent for a compound known as 3β-(4-methoxybenzyloxy)pregn-5-en-20-one. This specific pregnenolone derivative is designed for use in the treatment of cannabinoids-related disorders. The invention is particularly noteworthy for its potency in inhibiting the effects of THC. It has demonstrated the ability to inhibit both unconditioned and conditioned effects of THC, including THC self-administration and reinstatement in THC seeking in non-human primates. This patent represents a significant advancement in cannabinoid treatment options.
Career Highlights
Throughout his career, Sandy Fabre has worked with various organizations, including Aelis Farma and Université de Bordeaux. His experience in these institutions has allowed him to collaborate with other experts in the field and contribute to groundbreaking research.
Collaborations
Sandy has collaborated with notable colleagues such as Mathilde Metna and Monique Vallee. These partnerships have enriched his research and expanded the impact of his work in cannabinoid-related studies.
Conclusion
Sandy Fabre's innovative contributions to the treatment of cannabinoids-related disorders highlight his role as a significant inventor in the field. His patent and collaborations reflect a commitment to advancing medical research and improving patient outcomes.